Advertisement

Epidemiology and emm types of invasive group A streptococcal infections in Finland, 2008–2013

  • P. W. Smit
  • L. Lindholm
  • O. Lyytikäinen
  • J. Jalava
  • A. Pätäri-Sampo
  • J. Vuopio
Original Article

Abstract

Invasive Streptococcus pyogenes (group A streptococcus, GAS) infections are a major global cause of morbidity and mortality. We analysed the surveillance data on invasive GAS and the microbiological characteristics of corresponding isolates to assess the incidence and emm type distribution of invasive GAS infections in Finland. Cases defined as patients with isolations of blood and cerebrospinal fluid S. pyogenes are mandatorily notified to the National Infectious Disease Registry and sent to the national reference laboratory for emm typing. Antimicrobial data were collected through the network including all clinical microbiology laboratories. Pulsed-field gel electrophoresis (PFGE) analysis was performed to assess clonality. In total, 1165 cases of invasive GAS were reported in Finland during 2008–2013; the median age was 52 years (range, 0–100) and 54 % were male. The overall day 7 case fatality rate was 5.1 % (59 cases). The average annual incidence was 3.6 cases per 100,000 population. A total of 1122 invasive GAS isolates (96 %) were analysed by emm typing; 72 different emm types were identified, of which emm28 (297 isolates, 26 %), emm89 (193 isolates, 12 %) and emm1 (132 isolates, 12 %) were the most common types. During 2008–2013, an increase of erythromycin resistance (1.9 % to 8.7 %) and clindamycin (0.9 % to 9.2 %) was observed. This resistance increase was in parallel with the introduction of a novel clone emm33 into Finland. The overall incidence of invasive GAS infections remained stable over the study period in Finland. We identified clonal spread of macrolide-resistant invasive emm33 GAS type, highlighting the importance of molecular surveillance.

Keywords

Clindamycin Macrolide Resistance Clinical Microbiology Laboratory National Reference Laboratory Helsinki Region 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

The authors would like to thank Androulla Efstratiou and Aftab Jasir for critically reading the manuscript, the Finnish Study Group for Antimicrobial Resistance (FiRe), and Tuula Rantasalo and Toni Huovinen for the excellent technical assistance. This study was supported, in part, by the Academy of Finland (255636).

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Walker MJ, Barnett TC, McArthur JD, Cole JN, Gillen CM, Henningham A et al (2014) Disease manifestations and pathogenic mechanisms of group a Streptococcus. Clin Microbiol Rev 27:264–301. doi: 10.1128/CMR.00101-13 CrossRefPubMedCentralPubMedGoogle Scholar
  2. 2.
    Darenberg J, Henriques-Normark B, Lepp T, Tegmark-Wisell K, Tegnell A, Widgren K (2013) Increased incidence of invasive group A streptococcal infections in Sweden, January 2012–February 2013. Euro Surveill 18:pii=20443. Available online at: http://www.eurosurveillance.eu/images/dynamic/EE/V18N14/art20443.pdf
  3. 3.
    Syrogiannopoulos GA, Grivea IN, Al-Lahham A, Panagiotou M, Tsantouli AG, Michoula Ralf René Reinert AN et al (2013) Seven-year surveillance of emm types of pediatric Group A streptococcal pharyngitis isolates in Western Greece. PLoS One 8:e71558. doi: 10.1371/journal.pone.0071558 CrossRefPubMedCentralPubMedGoogle Scholar
  4. 4.
    Vähäkuopus S, Vuento R, Siljander T, Syrjänen J, Vuopio J (2012) Distribution of emm types in invasive and non-invasive group A and G streptococci. Eur J Clin Microbiol Infect Dis 31:1251–1256. doi: 10.1007/s10096-011-1436-2 CrossRefPubMedGoogle Scholar
  5. 5.
    Siljander T, Lyytikäinen O, Vähäkuopus S, Snellman M, Jalava J, Vuopio J (2010) Epidemiology, outcome and emm types of invasive group A streptococcal infections in Finland. Eur J Clin Microbiol Infect Dis 29:1229–1235. doi: 10.1007/s10096-010-0989-9 CrossRefPubMedGoogle Scholar
  6. 6.
    Rantala S, Vähäkuopus S, Siljander T, Vuopio J, Huhtala H, Vuento R et al (2012) Streptococcus pyogenes bacteraemia, emm types and superantigen profiles. Eur J Clin Microbiol Infect Dis 31:859–865. doi: 10.1007/s10096-011-1385-9 CrossRefPubMedGoogle Scholar
  7. 7.
    Nasser W, Beres SB, Olsen RJ, Dean MA, Rice KA, Long SW et al (2014) Evolutionary pathway to increased virulence and epidemic group A Streptococcus disease derived from 3,615 genome sequences. Proc Natl Acad Sci U S A 111:E1768–E1776. doi: 10.1073/pnas.1403138111 CrossRefPubMedCentralPubMedGoogle Scholar
  8. 8.
    Deresinski S (2014) Streptococcus pyogenes: the path to enhanced virulence. Clin Infect Dis 59:iii–iv. doi: 10.1093/cid/ciu351 CrossRefPubMedCentralGoogle Scholar
  9. 9.
    Aziz RK, Kotb M (2008) Rise and persistence of global M1T1 clone of Streptococcus pyogenes. Emerg Infect Dis 14:1511–1517. doi: 10.3201/eid1410.071660 CrossRefPubMedCentralPubMedGoogle Scholar
  10. 10.
    Seppälä H, Klaukka T, Vuopio-Varkila J, Muotiala A, Helenius H, Lager K et al (1997) The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med 337:441–446. doi: 10.1056/NEJM199708143370701 CrossRefPubMedGoogle Scholar
  11. 11.
    Gunell M, Jalava J (2014) Antimicrobial resistance in Finland- Finres 2012. National stitute for Health and Welfare, Helsinki, Finland. http://urn.fi/URN:ISBN:978-952-302-183-9
  12. 12.
    Siljander T, Karppelin M, Vähäkuopus S, Syrjänen J, Toropainen M, Kere J et al (2008) Acute bacterial, nonnecrotizing cellulitis in Finland: microbiological findings. Clin Infect Dis 46:855–861. doi: 10.1086/527388 CrossRefPubMedGoogle Scholar
  13. 13.
    Steer AC, Law I, Matatolu L, Beall BW, Carapetis JR (2009) Global emm type distribution of group A streptococci: systematic review and implications for vaccine development. Lancet Infect Dis 9:611–616. doi: 10.1016/S1473-3099(09)70178-1 CrossRefPubMedGoogle Scholar
  14. 14.
    Luca-Harari B, Darenberg J, Neal S, Siljander T, Strakova L, Tanna A et al (2009) Clinical and microbiological characteristics of severe Streptococcus pyogenes disease in Europe. J Clin Microbiol 47:1155–1165. doi: 10.1128/JCM.02155-08 CrossRefPubMedCentralPubMedGoogle Scholar
  15. 15.
    Lamagni TL, Darenberg J, Luca-Harari B, Siljander T, Efstratiou A, Henriques-Normark B et al (2008) Epidemiology of severe Streptococcus pyogenes disease in Europe. J Clin Microbiol 46:2359–2367. doi: 10.1128/JCM.00422-08 CrossRefPubMedCentralPubMedGoogle Scholar
  16. 16.
    Meehan M, Murchan S, Bergin S, O’Flanagan D, Cunney R (2013) Increased incidence of invasive group A streptococcal disease in Ireland, 2012 to 2013. Euro Surveill 18:20556. http://www.ncbi.nlm.nih.gov/pubmed/23968875 PubMedGoogle Scholar
  17. 17.
    Guy R, Williams C, Irvine N, Reynolds A, Coelho J, Saliba V et al (2014) Increase in scarlet fever notifications in the United Kingdom, 2013/2014. Euro Surveill 19:20749. doi:  10.2807/1560-7917.ES2014.19.12.20749 PubMedGoogle Scholar
  18. 18.
    Olafsdottir LB, Erlendsdóttir H, Melo-Cristino J, Weinberger DM, Ramirez M, Kristinsson KG et al (2014) Invasive infections due to Streptococcus pyogenes: seasonal variation of severity and clinical characteristics, Iceland, 1975 to 2012. Euro Surveill 19:5–15. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20784 PubMedGoogle Scholar
  19. 19.
    Turner CE, Abbott J, Lamagni T, Holden MTG, David S, Jones MD et al (2015) Emergence of a new highly successful acapsular group A Streptococcus clade of genotype emm89 in the United Kingdom. MBio 6:e00622-15. doi: 10.1128/mBio.00622-15 CrossRefPubMedCentralPubMedGoogle Scholar
  20. 20.
    Siljander T, Lyytikäinen O, Vähäkuopus S, Säilä P, Jalava J, Vuopio-Varkila J (2009) Rapid emergence of emm84 among invasive Streptococcus pyogenes infections in Finland. J Clin Microbiol 47:477–480. doi: 10.1128/JCM.01663-08 CrossRefPubMedCentralPubMedGoogle Scholar
  21. 21.
    Meisal R, Andreasson IKG, Høiby EA, Aaberge IS, Michaelsen TE, Caugant DA (2010) Streptococcus pyogenes isolates causing severe infections in Norway in 2006 to 2007: emm types, multilocus sequence types, and superantigen profiles. J Clin Microbiol 48:842–851. doi: 10.1128/JCM.01312-09 CrossRefPubMedCentralPubMedGoogle Scholar
  22. 22.
    Douthwaite S, Jalava J, Jakobsen L (2005) Ketolide resistance in Streptococcus pyogenes correlates with the degree of rRNA dimethylation by Erm. Mol Microbiol 58:613–622. doi: 10.1111/j.1365-2958.2005.04863.x CrossRefPubMedGoogle Scholar
  23. 23.
    Pesola AK, Sihvonen R, Lindholm L, Pätäri-Sampo A (2015) Clindamycin resistant emm33 Streptococcus pyogenes emerged among invasive infections in Helsinki metropolitan area, Finland, 2012 to 2013. Euro Surveill 20. pii: 21117Google Scholar
  24. 24.
    Bessen DE, Sotir CM, Readdy TL, Hollingshead SK (1996) Genetic correlates of throat and skin isolates of group A streptococci. J Infect Dis 173:896–900CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.European Public Health Microbiology Training Programme (EUPHEM)European Centre for Disease Prevention and Control (ECDC)StockholmSweden
  2. 2.Department of Infectious DiseasesNational Institute for Health and WelfareHelsinkiFinland
  3. 3.Department of Infections, Bacterial Infections UnitNational Institute for Health and WelfareTurkuFinland
  4. 4.Department of Infections, Infectious Disease Control UnitNational Institute for Health and WelfareHelsinkiFinland
  5. 5.Division of Clinical Microbiology, HUSLABHelsinki University HospitalHelsinkiFinland
  6. 6.Department of Medical Microbiology and ImmunologyUniversity of TurkuTurkuFinland

Personalised recommendations